Urinary DNA Methylation Test for Bladder Cancer Diagnosis.

ABSTRACT:

Importance

An accurate noninvasive biomarker test is needed for the early diagnosis of bladder cancer.

Objective

To evaluate the performance of a urinary DNA methylation test (PENK methylation) and compare its diagnostic accuracy with that of the nuclear matrix protein 22 (NMP22) test or urine cytology test.

Design, setting, and participants

In this prospective multicenter study at 10 sites in the Republic of Korea, individuals 40 years and older with hematuria undergoing cystoscopy within 3 months between March 11, 2022, and May 30, 2024, participated. The study participants were evaluated for bladder cancer using a urinary DNA methylation test.

Exposure

Urinary DNA methylation test, NMP22 test, and urine cytology test.

Main outcomes and measures

The pr

SUBMITTER: Jeong IG 

PROVIDER: S-EPMC11783243 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature